We are live on ! Find out more
CLLS

Cellectis

34 hedge funds and large institutions have $51.1M invested in Cellectis in 2025 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,000% more call options, than puts

Call options by funds: $63K | Put options by funds: $3K

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

116% more capital invested

Capital invested by funds: $23.7M → $51.1M (+$27.4M)

21% more funds holding

Funds holding: 2834 (+6)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

3.1% more ownership

Funds ownership: 11.53%14.63% (+3.1%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
34
Holders Change
+6
Holders Change %
+21.43%
% of All Funds
0.41%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
13
Increased
6
Reduced
5
Closed
6
Calls
$63K
Puts
$3K
Net Calls
+$60K
Net Calls Change
-$177K

CLLS Hedge Fund Activity: Q4 2025 in Review

34 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q4 2025, worth a combined $51.1M — up 116% from $23.7M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new CLLS positions and 6 closed out — a net gain of 7 holders — while 6 added to existing stakes and 5 trimmed.

The largest buyer was UBS AM, opening a new position worth an estimated $13.3M. The largest seller was Long Focus Capital Management, cutting an estimated $5.58M.

  • 34 institutional investors held Cellectis (CLLS) as of Q4 2025, up from 28 in Q3 2025.
  • Funds reported $51.1M of Cellectis stock for Q4 2025, up 116% quarter-over-quarter.
  • 13 funds opened new Cellectis positions in Q4 2025 and 6 closed out, a net change of +7 holders.
  • The largest Cellectis buyer in Q4 2025 was UBS AM, an estimated $13.3M added.
  • The largest Cellectis seller in Q4 2025 was Long Focus Capital Management, an estimated $5.58M sold.

Based on aggregated 13F filings for Q4 2025.